Skip to main content
SpringerLink
Log in

Adolescents and Young Adults with Acute Lymphoblastic Leukemia

  • Chapter
  • First Online:
Pediatric Acute Lymphoblastic Leukemia

  • 990 Accesses

Abstract

Acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs) is a relatively new concept for patients between the ages 15 and 39 years, who have unique pathophysiology and require specific clinical care. The results of many clinical studies demonstrated that treatment with the pediatric protocol has better disease-free survival and overall survival compared to treatment with the adult protocol for AYA-ALL. Survival of AYA-ALL was greatly improved to 70% due to pediatric regimens from 30% by adult regimen. There are two types of strategies for adapting pediatric regimen for AYA-ALL: one is pediatric-inspired regimen and the other is non-modified pediatric regimens. It is difficult to determine which of these two strategies should be recommended. New knowledge of specific genetical features of AYA-ALL will provide new strategies for targetable ALL, particularly Philadelphia-like ALL. Novel immunotherapies are approved for refractory and relapsed ALL. The firstline introduction of immunotherapy in BCP-ALL, kinase inhibitors in Ph-like ALL will further improve the outcome of AYA-ALL. Appropriate and long-term follow up by multidisciplinary care teams is needed to further improve survival and quality of life for survivors of AYA-ALL.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hunger SP, Mullighan CG. Acute Lymphoblastic leukemia in children. N Engl J Med. 2015;373(16):1541–52. https://doi.org/10.1056/NEJMra1400972.

    Article  CAS  PubMed  Google Scholar 

  2. Kantarjian BHM, Brien SO, Smith TL, Cortes J, Giles FJ, Beran M, et al. Results of treatment With hyper-CVAD, a dose-intensive regimen, in adult Acute lymphocytic leukemia. J Clin Oncol. 2000;18(3):547–61.

    Article  CAS  PubMed  Google Scholar 

  3. Stock W, Johnson JL, Stone RM, Kolitz JE, Powell BL, Wetzler M, et al. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of cancer and leukemia group B study 19802. Cancer. 2013;119(1):90–8.

    Article  CAS  PubMed  Google Scholar 

  4. Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood. 2009;113(7):1408–11.

    Article  CAS  PubMed  Google Scholar 

  5. Pulte D, Gondos A, Brenner H. Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990–2004. J Natl Cancer Inst. 2008;100(18):1301–9.

    Article  PubMed  Google Scholar 

  6. Trama A, Botta L, Foschi R, Ferrari A, Stiller C, Desandes E, et al. Survival of European adolescents and young adults diagnosed with cancer in 2000–07: population-based data from EUROCARE-5. Lancet Oncol. 2016;17(7):896–906. https://doi.org/10.1016/S1470-2045(16)00162-5.

    Article  PubMed  Google Scholar 

  7. Harrison CJ. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol. 2009;144(2):147–56.

    Article  PubMed  Google Scholar 

  8. Roberts KG. Genetics and prognosis of ALL in children vs adults. Hematology Am Soc Hematol Educ Program. 2018;2018(1):137–45. http://www.ncbi.nlm.nih.gov/pubmed/30504302%0A, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC6245970

    Article  PubMed  PubMed Central  Google Scholar 

  9. Reismüller B, Steiner M, Pichler H, Dworzak M, Urban C, Meister B, et al. High hyperdiploid acute lymphoblastic leukemia (ALL)—a 25-year population-based survey of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) study group. Pediatr Blood Cancer. 2017;64(6):1–8.

    Article  CAS  Google Scholar 

  10. Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood. 2010; 115(2):206–14.

    Google Scholar 

  11. Burmeister T, Gökbuget N, Schwartz S, Fischer L, Hubert D, Sindram A, et al. Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia. Haematologica. 2010;95(2):241–6.

    Article  CAS  PubMed  Google Scholar 

  12. Bassan R, Bourquin JP, DeAngelo DJ, Chiaretti S. New approaches to the management of adult acute lymphoblastic leukemia. J Clin Oncol. 2018;36(35):3504–19.

    Article  CAS  Google Scholar 

  13. Mullighan CG, Xiaoping S, Zhang J, Radtke I, Phillips LAA, Miller CB, Ma J, Liu W, Cheng C, Schulman BA, Harvey RC, Chen I-M, Clifford RJ, Carroll WL, Reaman G, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(5):470–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang Y-L, Pei D, et al. Targetable kinase-activating lesions in Ph-like Acute Lymphoblastic leukemia. N Engl J Med. 2015;371(11):1005–15.

    Article  CAS  Google Scholar 

  15. Roberts KG, Gu Z, Payne-Turner D, McCastlain K, Harvey RC, Chen IM, et al. High frequency and poor outcome of Philadelphia chromosome-like Acute Lymphoblastic leukemia in adults. J Clin Oncol. 2017;35(4):394–401.

    Article  PubMed  Google Scholar 

  16. Reshmi SC, Harvey RC, Roberts KG, Stonerock E, Smith A, Jenkins H, et al. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children’s oncology group. Blood. 2017;129(25):3352–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Boer JM, Koenders JE, Van Der Holt B, Exalto C, Sanders MA, Cornelissen JJ, et al. Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates. Haematologica. 2015;100(7):e261–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Boer JM, Marchante JRM, Evans WE, Horstmann MA, Escherich G, Pieters R, et al. BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/ErasmusMC and COG/St.Jude signatures. Haematologica. 2015;100:e354–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Tran TH, Loh ML. Ph-like acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016;2016(1):561–6.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Suzuki K, Okuno Y, Kawashima N, Muramatsu H, Okuno T, Wang X, et al. MEF2D-BCL9 fusion gene is associated with high-risk acute B-cell precursor lymphoblastic leukemia in adolescents. J Clin Oncol. 2016;34(28):3451–9.

    Article  CAS  PubMed  Google Scholar 

  21. Li J-F, Dai Y-T, Lilljebjörn H, Shen S-H, Cui B-W, Bai L, et al. Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. Proc Natl Acad Sci. 2018;115(50):E11711–20. https://doi.org/10.1073/pnas.1814397115.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Hirabayashi S, Ohki K, Nakabayashi K, Ichikawa H, Momozawa Y, Okamura K, et al. ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype. Haematologica. 2017;102(1):118–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Iacobucci I, Mullighan CG. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol. 2017;35(9):975–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol. 2012;30(14):1663–9.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Toft N, Birgens H, Abrahamsson J, Griškevic Ius L, Hallböök H, Heyman M, et al. Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia. Leukemia. 2018;32(3):606–15.

    Article  CAS  PubMed  Google Scholar 

  26. Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P, et al. What determines the outcomes for adolescents and young adults with acutelymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008;112(5):1646–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Testi AM, Valsecchi MG, Conter V, Vignetti M, Paoloni F, Giona F, et al. Difference in outcome of Adolescents with acute lymphoblastic leukemia (ALL) enrolled in pediatric (AIEOP) and adult (GIMEMA) protocols. Blood. 2004;104(11):1954 LP. http://www.bloodjournal.org/content/104/11/1954.abstract

    Article  Google Scholar 

  28. Ramanujachar R, Richards S, Hann I, Goldstone A, Mitchell C, Vora A, Rowe J, Webb D. Adolescents With Acute Lymphoblastic Leukaemia: Outcome on UK National Paediatric (ALL97) and adult(UKALLXII/E2993) trials. Pediatr Blood Cancer. 2007;48:254–61.

    Article  PubMed  Google Scholar 

  29. Boissel N, Auclerc MF, Lhéritier V, Perel Y, Thomas X, Leblanc T, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21(5):774–80.

    Article  PubMed  Google Scholar 

  30. Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009;27(6):911–8.

    Article  CAS  PubMed  Google Scholar 

  31. Storring JM, Minden MD, Kao S, Gupta V, Schuh AC, Schimmer AD, et al. Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Haematol. 2009;146(1):76–85.

    Article  PubMed  Google Scholar 

  32. Hayakawa F, Sakura T, Yujiri T, Kondo E, Fujimaki K, Sasaki O, et al. Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan adult leukemia study group. Blood Cancer J. 2014;4(10):e252–9. https://doi.org/10.1038/bcj.2014.72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133(14):1548–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab Ozogamicin versus standard therapy for Acute Lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–53. https://doi.org/10.1056/NEJMoa1509277.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Jabbour EJ, DeAngelo DJ, Stelljes M, Stock W, Liedtke M, Gökbuget N, et al. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. Cancer. 2018;124(8):1722–32.

    Article  CAS  PubMed  Google Scholar 

  36. Bhojwani D, Sposto R, Shah NN, Rodriguez V, Yuan C, Stetler-Stevenson M, et al. Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Leukemia. 2019;33(4):884–92. https://doi.org/10.1038/s41375-018-0265-z.

    Article  CAS  PubMed  Google Scholar 

  37. Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera J-M, et al. Blinatumomab versus chemotherapy for advanced Acute Lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–47. https://doi.org/10.1056/NEJMoa1609783.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522–31.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell Lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48. http://www.ncbi.nlm.nih.gov/pubmed/29385370%0A, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5996391

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in Acute Lymphoblastic leukemia. N Engl J Med. 2018;378(5):449–59. https://doi.org/10.1056/NEJMoa1709919.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Tai E, Buchanan N, Townsend J, Fairley T, Moore A, Richardson LC. Health status of adolescent and young adult cancer survivors. Cancer. 2012;118(19):4884–91. http://www.ncbi.nlm.nih.gov/pubmed/22688896%0A, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5292773

    Article  PubMed  Google Scholar 

  42. Salvador C, Meister B, Crazzolara R, Kropshofer G. Management of hypertriglyceridemia in children with acute lymphoblastic leukemia under persistent therapy with glucocorticoids and l-asparaginase during induction chemotherapy. Pediatr Blood Cancer. 2012;59(4):771.

    Article  PubMed  Google Scholar 

  43. Armenian SH, Hudson MM, Mulder RL, Chen MH, Constine LS, Dwyer M, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the international late effects of childhood cancer guideline harmonization group. Lancet Oncol. 2015;16(3):e123–36. https://doi.org/10.1016/S1470-2045(14)70409-7.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Vora A. Management of osteonecrosis in children and young adults with acute lymphoblastic leukaemia. Br J Haematol. 2011;155(5):549–60.

    Article  CAS  PubMed  Google Scholar 

  45. Salsman JM, Garcia SF, Yanez B, Sanford SD, Snyder MA. Victorson D. physical, emotional, and social health differences between post-treatment young adults with cancer and matched healthy controls. Cancer. 2014;120(15):2247–54. http://www.ncbi.nlm.nih.gov/pubmed/24888335%0A, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4121054

    Article  PubMed  Google Scholar 

  46. Smith AW, Keegan T, Hamilton A, Lynch C, Wu XC, Schwartz SM, et al. Understanding care and outcomes in adolescents and young adult with cancer: a review of the AYA HOPE study. Pediatr Blood Cancer. 2019;66(1):1–7.

    Article  Google Scholar 

  47. Zhang Y, Goddard K, Spinelli JJ, Gotay C, McBride ML. Risk of late mortality and second malignant neoplasms among 5-year survivors of young adult cancer: a report of the childhood, adolescent, and young adult cancer survivors research program. J Cancer Epidemiol. 2012;2012:1–11.

    Google Scholar 

  48. Ribera JM, Oriol A, Sanz MA, Tormo M, Fernández-Abellán P, Del Potro E, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the programa Español de tratamiento en hematología pediatric-based protocol ALL-96. J Clin Oncol. 2008;26(11):1843–9.

    Article  CAS  PubMed  Google Scholar 

  49. DeAngelo DJ, Stevenson KE, Dahlberg SE, Silverman LB, Couban S, Supko JG, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015;29(3):526–34.

    Article  CAS  PubMed  Google Scholar 

  50. Gokbuget N, Beck J, Brandt K, Bruggemann M, Burmeister T, Diedrich H, et al. Significant improvement of outcome in adolescents and young adults (AYAs) aged 15-35 years with acute lymphoblastic leukemia (ALL) with a pediatric derived adult ALL protokol; results of 1529 AYAs in 2 consecutive trial of the German multicenter study group for adult ALL (GMALL). Blood. 2013;122(21):abst 839.

    Article  Google Scholar 

  51. Barba P, Morgades M, Montesinos P, Gil C, Fox ML, Ciudad J, et al. Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials. Eur J Haematol. 2019;102(1):79–86.

    Article  PubMed  Google Scholar 

  52. Dombret H, Cluzeau T, Huguet F, Boissel N. Pediatric-like therapy for adults with ALL. Curr Hematol Malig Rep. 2014;9(2):158–64.

    Article  PubMed  Google Scholar 

  53. Bassan R, Masciulli A, Intermesoli T, Spinelli O, Tosi M, Pavoni C, et al. Final results of northern Italy leukemia group (NILG) trial 10/07 combining pediatric-type therapy with minimal residual disease study and risk-oriented hematopoietic cell transplantation in adult acute lymphoblastic leukemia (ALL). Blood. 2016;128(21):abst 176.

    Article  Google Scholar 

  54. Cluzeau T, Dhedin N, Huguet F, Raffoux E, Maury S, Mannone L, et al. Dose-intensity impacts on survival of adolescents and young adults with acute lymphoblastic leukemia treated in adult departments by a pediatric protocol (FRALLE 2000BT). Blood. 2012;120(21):abst 3561.

    Article  Google Scholar 

  55. Hough R, Rowntree C, Goulden N, Mitchell C, Moorman A, Wade R, et al. Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003. Br J Haematol. 2016;172(3):439–51.

    Article  CAS  PubMed  Google Scholar 

  56. Rijneveld AW, van der Holt B, Daenen SMGJ, Biemond BJ, de Weerdt O, Muus P, et al. Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40. Leukemia. 2011;25(11):1697–703. https://doi.org/10.1038/leu.2011.141.

    Article  CAS  PubMed  Google Scholar 

  57. Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, et al. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin–Frankfurt–Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016;91(8):819–23.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Kanagawa, Japan

    Etsuko Yamazaki

Authors
  1. Etsuko Yamazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Etsuko Yamazaki .

Editor information

Editors and Affiliations

  1. Department of Transplantation and Cell Therapy, Children’s Cancer, Center National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan

    Motohiro Kato

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Yamazaki, E. (2020). Adolescents and Young Adults with Acute Lymphoblastic Leukemia. In: Kato, M. (eds) Pediatric Acute Lymphoblastic Leukemia. Springer, Singapore. https://doi.org/10.1007/978-981-15-0548-5_12

Download citation

  • DOI: https://doi.org/10.1007/978-981-15-0548-5_12

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-15-0547-8

  • Online ISBN: 978-981-15-0548-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation